Retrophin (NASDAQ:RTRX) Lifted to Buy at BidaskClub

BidaskClub upgraded shares of Retrophin (NASDAQ:RTRX) from a hold rating to a buy rating in a research report sent to investors on Saturday, BidAskClub reports.

Other research analysts have also issued research reports about the company. BTIG Research initiated coverage on Retrophin in a research report on Tuesday, June 16th. They set a buy rating and a $25.00 price target for the company. Canaccord Genuity reaffirmed a buy rating and set a $26.00 price target on shares of Retrophin in a research report on Tuesday, May 19th. Zacks Investment Research raised Retrophin from a hold rating to a buy rating and set a $16.00 price target for the company in a research report on Monday, May 4th. ValuEngine downgraded Retrophin from a strong-buy rating to a buy rating in a report on Friday, April 17th. Finally, BMO Capital Markets upped their target price on Retrophin from $33.00 to $34.00 and gave the stock an outperform rating in a report on Tuesday, May 12th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of Buy and an average target price of $26.50.

NASDAQ RTRX opened at $20.41 on Friday. Retrophin has a 1-year low of $8.98 and a 1-year high of $21.95. The company has a current ratio of 5.97, a quick ratio of 5.88 and a debt-to-equity ratio of 0.92. The stock has a 50-day moving average of $16.32 and a 200-day moving average of $15.36. The firm has a market cap of $844.12 million, a PE ratio of -8.33 and a beta of 0.81.

Retrophin (NASDAQ:RTRX) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.70. Retrophin had a negative return on equity of 43.15% and a negative net margin of 57.01%. The company had revenue of $47.77 million during the quarter, compared to analyst estimates of $43.14 million. As a group, equities research analysts forecast that Retrophin will post -1.56 earnings per share for the current fiscal year.

In other Retrophin news, Director Steve Aselage sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. Following the transaction, the director now owns 238,732 shares in the company, valued at approximately $4,774,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 16,364 shares of company stock worth $298,850 in the last quarter. Company insiders own 4.63% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC grew its stake in shares of Retrophin by 103.1% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,970 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,000 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in shares of Retrophin in the 4th quarter worth approximately $50,000. SG Americas Securities LLC purchased a new stake in shares of Retrophin in the 1st quarter worth approximately $122,000. Calton & Associates Inc. purchased a new stake in shares of Retrophin in the 1st quarter worth approximately $158,000. Finally, Caxton Associates LP purchased a new stake in shares of Retrophin in the 4th quarter worth approximately $161,000.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Story: Cost of Capital

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.